We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings?
Read MoreHide Full Article
Key Takeaways
AbbVie's oncology franchise is projected at $1.75B in Q4 2025 sales, nearly 4% year-over-year growth.
ABBV's Venclexta, Epkinly and Elahere likely drove gains, partly offset by declining Imbruvica sales.
Investor focus stays on AbbVie's immunology drugs Humira, Rinvoq and Skyrizi ahead of Q4 results.
A meaningful portion of AbbVie’s (ABBV - Free Report) revenues comes from its oncology franchise. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the company has expanded its offerings into solid tumors. The newer drugs include Epkinly (for lymphoma), Elahere (for ovarian cancer) and Emrelis (for lung cancer), bringing the total to five oncology therapies. Sales of the oncology segment accounted for more than 11% of AbbVie’s total revenues in the first nine months of 2025, which grew 3% year over year.
Our model estimates that fourth-quarter 2025 sales for the overall oncology segment will be $1.75 billion, representing nearly 4% year-over-year growth. While Venclexta, Epkinly and Elahere are likely to have contributed to growth during the quarter, these gains may have been partially offset by the continued decline in Imbruvica sales amid rising competition from novel oral therapies. Since Emrelis was approved last year in May, we expect the drug’s sales to be modest during the quarter.
Though AbbVie’s oncology portfolio is contributing meaningfully, investor focus will largely remain on the company’s immunology franchise, which houses three flagship drugs, namely Humira, Rinvoq and Skyrizi. All eyes will be on the magnitude of their sequential growth and market share gains when the company reports fourth-quarter and full-year 2025 results on Feb. 4.
For AstraZeneca, oncology sales now account for 43% of total revenues. Sales in its oncology segment rose 16% year over year in the first nine months of 2025, driven by strong performance of medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounted for about 48% of MRK’s total revenues in the first nine months of 2025.
Pfizer’s oncology revenues grew 7% in the first nine months of 2025, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. The segment now accounts for more than 27% of Pfizer’s total revenues.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 15.19 times forward earnings, lower than its industry’s average of 17.56. The stock is also trading above its five-year mean of 13.56.
Image Source: Zacks Investment Research
The bottom-line estimate per share for 2025 has remained stable at $10.64 in the past 30 days, while those for 2026 have increased from $14.38 to $14.42 over the same time frame.
Image: Bigstock
Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings?
Key Takeaways
A meaningful portion of AbbVie’s (ABBV - Free Report) revenues comes from its oncology franchise. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the company has expanded its offerings into solid tumors. The newer drugs include Epkinly (for lymphoma), Elahere (for ovarian cancer) and Emrelis (for lung cancer), bringing the total to five oncology therapies. Sales of the oncology segment accounted for more than 11% of AbbVie’s total revenues in the first nine months of 2025, which grew 3% year over year.
Our model estimates that fourth-quarter 2025 sales for the overall oncology segment will be $1.75 billion, representing nearly 4% year-over-year growth. While Venclexta, Epkinly and Elahere are likely to have contributed to growth during the quarter, these gains may have been partially offset by the continued decline in Imbruvica sales amid rising competition from novel oral therapies. Since Emrelis was approved last year in May, we expect the drug’s sales to be modest during the quarter.
Though AbbVie’s oncology portfolio is contributing meaningfully, investor focus will largely remain on the company’s immunology franchise, which houses three flagship drugs, namely Humira, Rinvoq and Skyrizi. All eyes will be on the magnitude of their sequential growth and market share gains when the company reports fourth-quarter and full-year 2025 results on Feb. 4.
Competition in the Oncology Space
Other bigger players in the oncology space are AstraZeneca (AZN - Free Report) , Merck (MRK - Free Report) and Pfizer (PFE - Free Report) .
For AstraZeneca, oncology sales now account for 43% of total revenues. Sales in its oncology segment rose 16% year over year in the first nine months of 2025, driven by strong performance of medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounted for about 48% of MRK’s total revenues in the first nine months of 2025.
Pfizer’s oncology revenues grew 7% in the first nine months of 2025, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. The segment now accounts for more than 27% of Pfizer’s total revenues.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 15.19 times forward earnings, lower than its industry’s average of 17.56. The stock is also trading above its five-year mean of 13.56.
Image Source: Zacks Investment Research
The bottom-line estimate per share for 2025 has remained stable at $10.64 in the past 30 days, while those for 2026 have increased from $14.38 to $14.42 over the same time frame.
Image Source: Zacks Investment Research
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.